Table 1.
Patients’ characteristics in primary HCC (cohort P) and secondary HCC (cohort S) from mCRC
| Clinical features | Cohort P (n = 76) | Cohort S (n = 32) | P value | |
|---|---|---|---|---|
| Age (y) | ≤58 | 32 | 13 | 0.887 |
| >58 | 44 | 19 | ||
| Gender | Female | 39 | 14 | 0.473 |
| Male | 37 | 18 | ||
| Liver cirrhosis | No | 26 | 31 | 0.000 |
| Yes | 50 | 1 | ||
| HBsAg | Negative | 17 | 30 | 0.000 |
| Positive | 59 | 2 | ||
| Preoperative liver function (Child-Pugh) | A | 73 | 32 | 0.553 |
| NA | 3 | 0 | ||
| AFP | ≤18 ng/ml | 33 | 30 | 0.000 |
| >18 ng/ml | 42 | 2 | ||
| Tumor size | ≤5 cm | 51 | 26 | 0.138 |
| >5 cm | 25 | 6 | ||
| Tumor number | Single | 61 | 20 | 0.052 |
| Multiple | 15 | 12 | ||
| Vascular invasion | No | 63 | 29 | 0.384 |
| Yes | 13 | 3 | ||
| Pathological Grade | Well | 10 | 0 | NA |
| Moderate | 58 | 1 | ||
| Poor | 8 | 1 | ||
| NA | 0 | 30 | ||
| Neo-adjuvant treatments before operation | No | 72 | 28 | 0.233 |
| Yes | 4 | 4 | ||
| Adjuvant treatments after operation | Yes | 18 | 18 | 0.001 |
| No | 58 | 14 | ||
| Intra-hepatic recurrence | No | 44 | 29 | 0.001 |
| Yes | 32 | 3 | ||
| Extra-hepatic metastasis | No | 63 | 26 | 0.838 |
| Yes | 13 | 6 | ||
| AJCC Stage | 1 | 52 | NA | NA |
| 2 | 16 | NA | ||
| 3 + 3A | 8 | NA | ||
Abbreviations: AFP alpha-fetoprotein, AJCC American Joint Committee on Cancer, NA not available; Neo-adjuvant treatments before operation, including chemotherapy, preoperative portal vein embolization (PVE) and transcatheter arterial chemoembolization (TACE); Adjuvant treatments after operation, including lipiodol-iodine-131, chemotherapy, TACE
Significant data are highlighted in bold